The failure of these trials may be due to too-high levels of BACE1 inhibition often targeted to reduce Aβ levels by >70% at the highest dose and too-late applications to AD stages manifesting cognitive symptoms with extensive Aβ accumulation (McDade et al., 2021; Ohno, 2024, 2025). The gene discussed is BACE1; the disease is Alzheimer disease.